Sunday 18 October 2026
Export ACIU’s income statement to Excel — free account
AC Immune
ACIU Healthcare Biotechnology
AC Immune’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 86.1% from fiscal 2024. In the quarter to June 2026, revenue grew 29.7%, EPS grew 9.52% and free cash flow grew 4.66%, each against the same quarter a year earlier.
2.39
0.06
−2.45%
Follow ACIU
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | (113.59%) | (93.59%) | (74.66%) |
+8 more TTM periods Free account |
|
| 0.00% | (70.48%) | (37.92%) | (34.34%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 639.62% | (1,753.26%) | (386.29%) | |
Average Days of Receivables |
0.00 | 128.71 | 99.90 | 154.48 | |
Free Cash Flow per Share |
0.00 | 0.00 | (0.84) | (0.61) | |
Free Cash Flow |
(83.67) | — | (84.67) | (61.41) | |
Capital Expenditures |
(1.21) | — | (1.07) | (1.06) | |
| Other line items | |||||
Cash ROIC |
(59.83%) | 0.00% | (51.47%) | (28.76%) | |
Accounts Receivable Turnover |
0.00 | 2.41 | 3.54 | 0.30 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | 1,409.69% | 1,579.52% | 1,552.05% | |
Selling, General and Administrative Expense of Revenue |
— | 426.99% | 450.44% | 399.86% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 123.03% | 115.05% | |
Interest Coverage |
— | (319.62) | (362.82) | (409.74) | |
Operating CF/Net income |
0.00 | 0.00 | 0.98 | 0.71 | |
Depreciation/Fixed assets |
1.49 | 0.00 | 1.26 | 1.04 | |
Capex/Depreciation |
(0.33) | — | (0.35) | (0.37) | |
Revenue per Share |
— | 0.05 | 0.04 | 0.05 | |
Operating CF per Share |
0.00 | 0.00 | (0.83) | (0.60) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.25 | 0.23 |
Columns are period end dates